Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
39.93%
Operating Margin
16.00%
Net Margin
13.99%
Efficiency Metrics
Revenue per Expense Ratio
1.19
R&D as % of Revenue
3.12%
Earnings Quality
EBITDA Margin
26.12%
Income Tax Rate
4.51%
EPS
15.5300000000
Balance Sheet Analysis
Current Ratio
1.75
Cash Ratio
0.58
Working Capital
$10.58B
Debt to Equity
0.75
Debt to Assets
35.37%
Equity Ratio
47.34%
Cash Flow Analysis
Operating Cash Flow Ratio
19.61%
Free Cash Flow Ratio
16.16%
CapEx to Revenue
3.45%
Dividends Paid
$523.00M
Stock Buybacks
$3.00B
Total Shareholder Returns
$3.52B
Cash Position Change
-5.38%
Key Takeaways (2023 FY)
Revenue declined by 4.5819881999332%, indicating potential market challenges
Increased dividend payments by 16.73%
Detailed Growth Metrics
Core Performance
Revenue
-4.58%
Net Income
-13.74%
EPS
-12.41%
Operating Income
-18.28%
Operational Efficiency
R&D Expenses
-9.11%
SG&A Expenses
18.49%
Operating Cash Flow
-8.17%
Free Cash Flow
0.23%
Balance Sheet Health
Assets
1.62%
Debt
1.24%
Book Value per Share
7.75%
Inventory
-9.69%
Shareholder Returns
Dividends per Share
16.73%
Shares Outstanding
-1.53%
Long Term Trends
3Y Revenue/Share
36.47%
5Y Revenue/Share
83.24%
3Y Dividend/Share
59.21%
5Y Dividend/Share
104.77%